Q-omics provides the consensus-scored RSPH6A profile across patient tissues and cancer cell-line models. RSPH6A expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RSPH6A is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, RSPH6A RNA expression shows 7,829 significant gene co-expression associations, with the highest sampling consensus in THCA. Together, these results highlight HNSC, and THCA as cancer lineages where RSPH6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSPH6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSPH6A survival associations across molecular data types. RSPH6A RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSPH6A RNA expression–survival associations across cancer types. High RSPH6A expression shows unfavorable associations in ACC, KICH and LIHC, but favorable associations in HNSC, UCEC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RSPH6A RNA expression.
This table summarizes RSPH6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RSPH6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSPH6A shows lower tumor expression in THCA and BRCA and higher tumor expression in HNSC, UCEC, CHOL and LUAD. The THCA box plot shows higher RSPH6A RNA expression in normal versus tumor tissue (log2 FC = −2.204, t-test p < 0.001).
This table shows molecular features associated with RSPH6A in patient tissues and cancer cell lines. In patient samples, RSPH6A shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RSPH6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
